Squarepoint Ops LLC Has $2.13 Million Holdings in Qiagen (NYSE:QGEN)

Squarepoint Ops LLC trimmed its position in Qiagen (NYSE:QGEN - Free Report) by 47.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 47,847 shares of the company's stock after selling 43,627 shares during the quarter. Squarepoint Ops LLC's holdings in Qiagen were worth $2,131,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Groupama Asset Managment raised its stake in Qiagen by 8,074.0% during the fourth quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock worth $1,416,844,000 after acquiring an additional 32,216,761 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Qiagen by 9.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock valued at $1,127,470,000 after purchasing an additional 2,202,040 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Qiagen by 2.5% during the 4th quarter. Wellington Management Group LLP now owns 21,782,305 shares of the company's stock valued at $970,534,000 after purchasing an additional 531,362 shares during the last quarter. Vanguard Group Inc. increased its position in Qiagen by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company's stock worth $397,937,000 after purchasing an additional 77,119 shares in the last quarter. Finally, Norges Bank bought a new position in Qiagen in the 4th quarter valued at approximately $181,529,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on QGEN shares. Robert W. Baird upped their target price on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Wall Street Zen raised Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 15th. Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Baird R W lowered shares of Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Finally, UBS Group decreased their price target on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Qiagen has an average rating of "Hold" and an average target price of $48.42.

Qiagen Trading Up 0.3%

QGEN stock traded up $0.13 during trading on Friday, hitting $45.13. The company had a trading volume of 2,518,914 shares, compared to its average volume of 1,165,783. The stock has a market cap of $10.03 billion, a PE ratio of 125.66, a PEG ratio of 2.39 and a beta of 0.67. The business has a 50-day moving average of $41.70 and a 200-day moving average of $41.87. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38. Qiagen has a one year low of $37.63 and a one year high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.50 by $0.05. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The firm had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. During the same quarter in the previous year, the company earned $0.44 EPS. The company's revenue for the quarter was up 5.2% on a year-over-year basis. Research analysts predict that Qiagen will post 2.26 earnings per share for the current fiscal year.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.